CRISPR Gene-Therapy: A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making

Victor Lange*, Klemens Kappel

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

47 Downloads (Pure)

Abstract

CRISPR is currently viewed as the central tool for future gene therapy. Yet, many prominent scientists and bioethicists have expressed ethical concerns around CRISPR gene therapy. This paper provides a critical review of concerns about CRISPR gene therapy as expressed in the mainstream academic literature, paired with replies also generally found in that literature. The expressed concerns can be categorised into three types depending on whether they stress risk/benefit ratio, autonomy and informed consent, or concerns related to various aspects of justice. In the reviewed literature, we found no intrinsic objections to CRISPR gene therapy, even though many such objections were present in discussions of gene editing in the 1990s. The paper then proposes a brief outline for a practically applicable moral framework for public decision-making about CRISPR gene therapy and suggests how such a framework might be supported. We also suggest that this framework should govern public engagement about CRISPR gene therapy in order to reduce the risk that we make decisions about CRISPR gene therapy based on misperceptions, inflated views of risk, or unreasonable moral or religious views.

Original languageEnglish
JournalCanadian Journal of Bioethics
Volume5
Issue number2
Pages (from-to)78-87
Number of pages10
ISSN1923-2799
DOIs
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© Victor Lange and Klemens Kappel, 2022.

Keywords

  • biotechnology
  • convergence
  • CRISPR
  • gene therapy
  • mid-level principles
  • public engagement

Cite this